Detailed company information
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 05, 2026
Earnings Transcript for 2026 - Q1Released: May 04, 2026
Earnings Transcript for 2025 - Q4Released: Mar 04, 2026
Earnings Transcript for 2025 - Q3Released: Nov 08, 2025
Earnings Transcript for 2025 - Q2Released: Aug 05, 2025
Earnings Transcript for 2025 - Q1Released: May 07, 2025
Earnings Transcript for 2024 - Q4Released: Mar 04, 2025
Earnings Transcript for 2024 - Q3Released: Nov 06, 2024
Earnings Transcript for 2024 - Q2Released: Jul 31, 2024
Earnings Transcript for 2024 - Q1Released: May 07, 2024
Earnings Transcript for 2023 - Q4Released: Mar 07, 2024
Earnings Transcript for 2023 - Q3Released: Nov 07, 2023
Earnings Transcript for 2023 - Q2Released: Aug 02, 2023
Earnings Transcript for 2023 - Q1Released: May 09, 2023
Earnings Transcript for 2022 - Q4Released: Mar 08, 2023
Earnings Transcript for 2022 - Q3Released: Nov 08, 2022
Earnings Transcript for 2022 - Q2Released: Aug 02, 2022
Earnings Transcript for 2022 - Q1Released: May 10, 2022
Earnings Transcript for 2021 - Q4Released: Mar 03, 2022
Earnings Transcript for 2021 - Q3Released: Nov 02, 2021
Earnings Transcript for 2021 - Q2Released: Aug 04, 2021
Earnings Transcript for 2021 - Q1Released: May 12, 2021
Earnings Transcript for 2020 - Q4Released: Mar 24, 2021
Earnings Transcript for 2020 - Q2Released: Aug 10, 2020
ANIP ANI Pharmaceuticals, Inc.
Evolus, Inc.'s Q2 2026 Evolysse sampling program is set to significantly boost revenue, contributing an estimated 10%-12% to total revenues in 2026 and driving further growth in 2027 and beyond.
Read post
Dafinchi
